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A B S T R A C T
Human babesiosis is a zoonosis primarily transmitted through Ixodes ticks and alternatively by routes
such as blood transfusions from asymptomatic donors. We report the ﬁrst case of human babesiosis
caused by Babesia divergens in a patient with HIV. This study also focuses on elucidating the possible
transmission route of infection in this patient, who received numerous blood transfusions but showed
patent symptoms only after splenectomy. A battery of detection tools along with a novel Western-Blot
Assay and Enzyme Linked Immunosorbent Assay using the major surface protein of B. divergens (Bd37) as
a target were used to evaluate the presence of B. divergens or antibodies against the parasite in samples
from the patient and the blood donors involved in this case. A retrospective study of the humoral status
against the parasite revealed B. divergens IgG antibodies in one of the implicated donors, but also showed
that the patient had been already exposed to the parasite before any transfusion. Thus, this analysis of
natural and transfusion transmission routes suggests a pre-existing subclinical babesiosis in the patient.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idHuman babesiosis is an expanding zoonosis transmitted
through ticks. Babesia microti, B. divergens, B. duncani, B. venatorum,
and B. divergens-like organisms (1) are responsible for the human
disease, causing a febrile illness similar to malaria. Transmission of
B. microti and B. duncani via blood transfusion from infected
asymptomatic donors has also been reported. The spread of Babesia
through transfusions is increasingly a problem and is one of the
most commonly reported transfusion-transmitted infections in
the USA. B. divergens is considered the main agent of human
babesiosis in Europe (1). Although B. divergens also meets the
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).blood components, no transfusion transmission has been reported
yet. We report the ﬁrst case of babesiosis caused by B. divergens in
an immunocompromised patient with HIV.
1. The patient
A 37-year-old man from Spain, newly diagnosed with HIV
infection, showed plasma HIV RNA levels of 277,000 copies/mL and
a CD4+ T cell count of 178/mL at diagnosis. The patient was
admitted to a tertiary University Hospital in Madrid, Spain. Two
weeks after starting the antiretroviral therapy, a hemophagocytic
syndrome developed in the patient, possibly as part of an immune
restoration syndrome, and he received multiple blood transfu-
sions. To control his progressive deterioration, the patient
underwent an elective splenectomy. After a slow recovery, the
patient showed a new decline in his general condition, without
relevant microbiological ﬁndings. About three weeks later, the
patient was admitted to the ICU with acute respiratory distress
syndrome, transfused again and treated empirically with multiple
broad-spectrum antibiotics, antifungals and appropriate drugs for
Mycobacterium tuberculosis and M. avium-intracellulare, withoutciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Detection of B. divergens and anti-parasite antibodies at diagnosis and follow up of
the HIV-patient using microscopy, PCR, Western blot, ELISA and IFA assays. (PC) A
serum sample of a patient who suffered a severe babesiosis caused by B. divergens
was kindly provided by Dr. Lappalainen5 and used as a positive control. (NC) A sera
pool from humans negative for malaria, toxoplasmosis, leishmaniasis, ﬁlariasis, and
some others was kindly provided by the Unit of Serologic Diagnosis of Parasitic









PCR WB ELISA IFA
IgG IgM IgG IgM IgG
Patient 1 Not donea Not donea +c -c +c -c +c
2 + + +c -c +c -c +c
3 - - +c -c +c -c +c
4 - - +d -d +d -d +d
Donor Not doneb Not doneb + - + - +
PC + + + + +
NC - - - - -
(a) No speciﬁc studies were done for parasites. (b) In spite of an active search the
donor was not found. (c) Pre-transfusion patient’s sera samples and (d) Post-
transfusion patient’s sera samples collected during 4 months.
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Giemsa-stained thin ﬁlm from peripheral blood showed a few
intraerythrocytic parasites compatible with Babesia spp. A 156 bp
fragment encoded by the variable region V4 of the B. divergens 18S
rRNA gene (from thymine 609 to guanine 764) was ampliﬁed from
the patient’s blood by PCR by using F4Bd (50-ttgcgtggtgttaatat-30)
and R1 Mx (50-ccaacaaaatagaaccaaagtcc-30) primers. The fragment
showed 100% identity to B. divergens and differed to B. divergens
like (BLASTN 2.2.30) conﬁrming the presence of B. divergens
parasites. Speciﬁc treatment for Babesia was started immediately
with quinine plus clindamycin, later changed to azithromycin and
atovaquone for lower toxicity. The patient’s condition showed a
clear improvement and he was discharged from the ICU two weeks
later. The patient was found free of parasites by PCR in subsequent
follow up visits.
Natural (tick) and transfusion-transmission sources of Babesia
were considered in an effort to trace the possible route of infection.
Cattle and wild mammals are hosts for B. divergens1. The patient
lived in Spain, and was the owner of a cat but did not have contact
with dogs or other domestic and farm animals. The medical history
of the patient included frequent travel to various European
countries. In particular, a few weeks before his medical crisis, the
patient had travelled to Berlin and visited public green parks, but
no pasture or wooded areas. Of note, ticks infected with B. microti,
B. venatorum and B. divergens have been recently observed in some
urban areas from Germany2, but the patient did not recall recent
tick bites.
Because the patient’s route of infection did not seem to follow
the natural tick-mammal route for acquisition of B. divergens1, we
investigated transfusion-transmitted babesiosis (TTB) as an
alternative route. During his hospital stay, the patient received
numerous RBC and platelets transfusions. To ﬁnd a potential
source of infection, repository sample sera from 27 blood donors
involved in erythrocyte transfusions to the patient were tested
retrospectively.
The sequence encoding Asn28 to Phe341 of the major surface
antigen of B. divergens, Bd373, were cloned into the expression
vector pGEX-4T (GE Healthcare Bio-sciences AB, Uppsala, Sweden),
expressed in E. coli BL21 (DE) and puriﬁed as recombinant Bd37-
GST (Glutathione S-Transferase) fusion protein following manu-
facturer’s instructions. This protein was then used as a target
substrate for both Western blot assay and Enzyme Linked
Immunosorbent Assay (ELISA)4 to assess the presence of anti-
bodies in the patient and donors. Indirect Immunoﬂuorescence
Assay (IFA) on smears of parasitized RBCs was also performed to
detect anti-parasite antibodies. The tests revealed the presence of
speciﬁc antibodies against B. divergens by IFA and speciﬁc anti-
Bd37 IgG antibodies by WB and ELISA in just one serum sample of a
blood donor from a rural area of Spain (Table 1, Supplementary
ﬁles S1 and S2). Two days before the Babesia detection by
microscopy, the patient had received a packed erythrocytes
concentrate from this positive donor, who therefore could be
considered as a possible source of infection in our case.
Unfortunately, this donor could not be located, preventing us
from performing further analysis such as genotyping the infecting
strain. A retrospective study was also performed with six pre-
transfusion and three post-transfusion sera samples from the
patient. Surprisingly, these samples showed the presence of anti-B.
divergens IgG by IFA and anti-Bd37 IgG antibodies detected by WB
and ELISA in as early as the ﬁrst blood sample collected at the
beginning of his hospital admission. As a consequence, we could
not conﬁrm TTB leading to patient’s sero-conversion (Supplemen-
tary ﬁles S1 and S2). Since the patient was Babesia-seropositive
before any transfusion, natural acquisition of the infection and the
recent visits of the patient to urban green areas were reconsidered.
To ﬁnd out whether the patient had acquired the Babesia infectionrecently, serologic testing for speciﬁc IgM was performed by WB
(Supplementary ﬁle S2) and ELISA. B. divergens IgM antibodies
could not be detected in sera samples from the patient. This could
indicate that the B. divergens infection was not recently acquired,
but rather was a pre-existing subclinical babesiosis with a low-
grade parasitemia that ﬂourished following splenectomy and the
immune decline of the patient.
2. Discussion
We have reported what we think is the ﬁrst case of a patient
coinfected with HIV and B. divergens. HIV-derived immunosup-
pression and the splenectomy probably co-contributed to the
clinical ﬂourishing of the babesiosis. The report also focuses on
elucidating the transmission route of the Babesia infection to the
patient.
The use of the recombinant Bd37 protein in WB and ELISA along
with IFA allowed us to identify B. divergens IgG antibodies in one of
the implicated blood donors, but also revealed that the patient had
been already exposed to the parasite before transfusions.
Additional evidence that the infection was not recently acquired
was obtained from the lack of B. divergens IgM antibodies in sera
samples from the patient.
As for most emerging infectious diseases, many epidemiological
parameters remain unknown: the proportion of undetected
babesiosis cases, the prevalence of babesiosis in blood donors,
and the risk of getting a Babesia infection following blood
transfusion is not well established. Babesia infected ticks and
their vertebrate hosts are present in urban, rural and natural areas
of Europe. Infection by B. divergens and B. venatorum may follow a
protracted course, representing a threat to the blood supply which
could lead to TTB cases. Signiﬁcant seroprevalence rates have been
documented in Europe1 although only around 50 cases of Babesia
infections have been reported in the continent so far1. This low
number of cases invites us to think about asymptomatic carriers
going undetected or to misdiagnosis of symptomatic patients.
Thus, to fully recognize the status of babesiosis in Europe, sensitive
and speciﬁc assays capable of detecting the infection are needed to
provide robust data for diagnosis, track alternative transmission
routes of infection, determine seroprevalence rates in the blood
donor population, and thus improve the safety of the blood supply.
Supplementary ﬁle S1. The IFA test revealed speciﬁc anti-
B. divergens (Bd Rouen 1987 strain) antibodies in sera of the patient
L.M. Gonza´lez et al. / International Journal of Infectious Diseases 33 (2015) 202–204204and the positive donor. B. divergens smears were performed using
intra-erythrocytic forms (A and D) and free parasites (B, C, and E)
prepared from in vitro human erythrocyte cultures. All sera samples
were diluted at 1:128 and the IgG speciﬁc antibodies were detected
with goat anti-human IgG antibodies conjugated to ﬂuorescein
isothiocyanate (FITC). A and B: serum sample of the patient collected
at the beginning of hospital admission. C: serum sample of the
positive donor. D and E: negative control (NC). Column 1: Infected
blood cells or free merozoites captured by differential interference
contrast (DIC). Column 2: DAPI-stained nucleic acids (shown in
blue). Column 3: Fluorescing intraerythrocytic parasites or isolated
free extracellular merozoites probed with IgG antibodies from the
sera samples. Column 4 shows all images overlaid.
Supplementary ﬁle S2. Serological detection of speciﬁc anti-B.
divergens IgG and IgM antibodies. WB and ELISA were prepared
using recombinant Bd37-GST (59.5 kDa), and GST fusion partner
for Bd37 (26 kDa). Speciﬁcity for the patient’s and donor’s sera
against recombinant Bd37 from B. divergens was observed by WB.
Sera samples were diluted and the speciﬁc cutoff was applied at
1:200 for WB by using 150 ng of each of Bd37 and GST recombinant
proteins and probing with IgG (A and B) and IgM (C and D). Bd37
(Panel A) and GST (Panel B) recombinant proteins subjected to
SDS-PAGE. Lane 1: positive control (PC). Lane 2: the serum sample
of the patient collected at the beginning of hospital admission
(early January). Lane 3: the serum sample of the positive donor.
Line 4: One of the 26 sera samples from negative donors. Lane 5:
negative control (NC). Lane 6 a pool of donors infected by B. microti
(kindly provided by LFKRI New York Blood Center, New York, NY)
did not recognize the recombinant Bd37 protein. None of the sera
reacted with the recombinant GST protein. E. Detection of B.
divergens IgG antibodies by ELISA using the positive control (PC),
the negative control (NC) and the positive donor sera samples
(symbols and lines in black), six pre-transfusion sera samples from
the patient collected between early January to mid-February
(symbols and lines in grey) and three post-transfusion sera
samples collected between late February to early May (symbols
and dotted lines in grey). Samples were diluted 1:100 to 1:800.Although all infected sera showed higher OD values than the NC
sample in a dilution-dependent manner at dilutions 1:100, 1:200
and 1:400, no signiﬁcant differences in reactivity between pre-
transfusion and post-transfusion sera were observed.
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